8-K: NeuroOne Medical Technologies Faces Nasdaq Delisting Threat Due to Low Share Price

NeuroOne Medical Technologies Corporation received a notification from Nasdaq regarding non-compliance with the minimum bid price requirement for continued listing.

Summary

• NeuroOne Medical Technologies Corporation received a notice from Nasdaq on May 6, 2025, stating that it is not in compliance with the minimum bid price requirement because its common stock price has been below $1.00 per share for 30 consecutive business days.
• The company has 180 calendar days, until November 3, 2025, to regain compliance.
• Compliance can be achieved if the closing bid price of the company's common stock closes at or above $1.00 per share for a minimum of 10 consecutive business days.
• If compliance is not achieved by November 3, 2025, the company may be eligible for an additional 180 days if it meets certain market value and listing requirements.
• If the company fails to cure the deficiency or is otherwise ineligible, Nasdaq will provide notice that the company's securities will be subject to delisting.
• The company intends to monitor the stock price and consider options to regain compliance.
• There is no assurance that the company will regain compliance or maintain compliance with other Nasdaq listing requirements.

Sentiment

Score: 3

Explanation: The sentiment is negative due to the delisting notice, indicating financial vulnerability and potential loss of investor confidence. However, the company has a chance to regain compliance.

Positives

• The company has a period of 180 days to regain compliance with the Nasdaq's minimum bid price requirement.
• The company may be eligible for an additional 180-day extension to regain compliance if it meets certain requirements.
• The company intends to actively monitor the stock price and consider available options to resolve the deficiency.

Negatives

• The company's common stock price has been below $1.00 per share for 30 consecutive business days, leading to non-compliance with Nasdaq's minimum bid price requirement.
• Failure to regain compliance within the allotted time could result in delisting from the Nasdaq Capital Market.
• There is no assurance that the company will regain compliance or maintain compliance with other Nasdaq listing requirements.

Risks

• The company faces the risk of being delisted from the Nasdaq Capital Market if it fails to regain compliance with the minimum bid price requirement.
• The company's stock price may be negatively impacted by the delisting notice.
• There is uncertainty regarding the company's ability to regain compliance within the given timeframe.

Future Outlook

The company intends to actively monitor the closing bid price for its common stock and will consider available options to resolve the deficiency and regain compliance with the Minimum Bid Price Requirement.

Management Comments

• David Rosa, Chief Executive Officer, signed the report on behalf of NeuroOne Medical Technologies Corporation.

Industry Context

Delisting notices are not uncommon for companies, especially smaller ones, in the biotech and medical device sectors, which can be volatile and subject to regulatory hurdles and clinical trial outcomes.

Comparison to Industry Standards

• Many small-cap biotech companies face similar challenges with maintaining share price compliance on major exchanges.
• Companies like Second Sight Medical Products and Diffusion Pharmaceuticals have faced similar delisting warnings in the past.
• The ability to regain compliance often depends on positive clinical trial results, regulatory approvals, or strategic partnerships that can boost investor confidence.

Stakeholder Impact

• Shareholders may experience a decline in the value of their investment if the company is delisted.
• Employees may face uncertainty regarding their job security if the company's financial situation worsens.
• The company's ability to raise capital and fund its operations may be negatively impacted.

Next Steps

• The company will actively monitor the closing bid price of its common stock.
• The company will consider available options to resolve the deficiency and regain compliance with the Minimum Bid Price Requirement.
• The company may appeal a delisting determination to a Nasdaq hearings panel if necessary.

Key Dates

Keywords

delisting, Nasdaq, minimum bid price, compliance, NeuroOne Medical Technologies, stock price